HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toos A H H Daemen Selected Research

p53 synthetic long peptide vaccine

10/2015A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toos A H H Daemen Research Topics

Disease

1Ovarian Epithelial Carcinoma
10/2015
1Fatigue
10/2015
1Neoplasms (Cancer)
10/2015
1Ovarian Neoplasms (Ovarian Cancer)
10/2015

Drug/Important Bio-Agent (IBA)

1p53 synthetic long peptide vaccineIBA
10/2015
1peginterferon alfa-2b (Pegintron)FDA Link
10/2015
1GemcitabineFDA Link
10/2015
1Peptides (Polypeptides)IBA
10/2015
1PlatinumIBA
10/2015
1VaccinesIBA
10/2015

Therapy/Procedure

1Drug Therapy (Chemotherapy)
10/2015
1Immunotherapy
10/2015